CliffBio
biologic

Baygam, Gamastan S/D

Immune Globulin (Human)

Loss of exclusivityJanuary 1956projected — 12-year biologic exclusivity estimate
CompanyGrifols →See this company's full patent-cliff portfolio

Drug detail

Brand nameBaygam, Gamastan S/D
Active ingredientImmune Globulin (Human)
Strength16.50%
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 1944
Marketing statusRx

More from Grifols

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Baygam, Gamastan S/D patent cliff — loss of exclusivity January 1956 | CliffBio